Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries

Abstract

Introduction Pharmacoepidemiological data suggest that lithium prescriptions for bipolar disorder are gradually decreasing, with less attention having been paid to other indications.

Methods We examined lithium prescriptions between 1994 and 2017 in data provided by the Drug Safety in Psychiatry Program AMSP, including psychiatric hospitals in Germany, Austria and Switzerland. We compared lithium use for different diagnoses before and after 2001 and in three periods (T1: 1994–2001, T2: 2002–2009, and T3: 2010–2017).

Results In a total of 158,384 adult inpatients (54% female, mean age 47.4±17.0 years), we observed a statistically significant decrease in lithium prescriptions between 1994–2000 and 2001–2017 in patients with schizophrenia spectrum disorder from 7.7% to 5.1% and in patients with affective disorders from 16.8% to 9.6%. Decreases in use were also observed for diagnostic subgroups: schizoaffective disorder (ICD-10 F25: 27.8% to 17.4%), bipolar disorder (F31: 41.3% to 31%), depressive episode (F32: 8.1% to 3.4%), recurrent depression (F33: 17.9% to 7.5%, all: p<0.001) and emotionally unstable (borderline) personality disorder (6.3% to 3.9%, p=0.01). The results in T1 vs. T2 vs. T3 were for F25: 26.7% vs. 18.2% vs. 16.2%, F32: 7.7% vs. 4.2% vs. 2.7%, F33: 17.2% vs. 8.6% vs. 6.6% and for F31: 40.8% vs. 31.7% vs 30.0%, i. e. there was no further decrease for lithium use in bipolar disorder after 2002. Lithium’s main psychotropic co-medications were quetiapine (21.1%), lorazepam (20.6%), and olanzapine (15.2%).

Discussion In inpatients, the use of lithium has decreased in patients with bipolar disorder and also with various other psychiatric diagnoses.

Keywords

lithium - pharmacoepidemiology - bipolar disorders - polypharmacy - psychopharmacology

^‡ equal contribution: Waldemar Greil, Mateo de Bardeci

Publikationsverlauf

Eingereicht: 13. März 2024

Angenommen nach Revision: 26. Juni 2024

Artikel online veröffentlicht:
22. August 2024

• References

• 1 Yatham LN, Kennedy SH, Parikh SV. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97-170
• 2 Ercis M, Ozerdem A, Singh B. When and how to use lithium augmentation for treating major depressive disorder. J Clin Psychiatry 2023; 84: 23ac14813
• 3 Leucht S, Helfer B, Dold M. et al. Lithium for schizophrenia. Cochrane Database Syst Rev 2015; 2015: CD003834
• 4 Antolin-Concha D, Lahteenvuo M, Vattulainen P. et al. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study. J Affect Disord 2020; 277: 885-892
• 5 Lewitzka U, Severus E, Bauer R. et al. The suicide prevention effect of lithium: More than 20 years of evidence-a narrative review. Int J Bipolar Disord 2015; 3: 32
• 6 Queissner R, Lenger M, Birner A. et al. The association between anti-inflammatory effects of long-term lithium treatment and illness course in Bipolar Disorder. J Affect Disord 2020; 281: 228-234
• 7 Forlenza OV, Diniz BS, Radanovic M. et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br J Psychiatry 2011; 198: 351-356
• 8 Rhee TG, Olfson M, Nierenberg AA. et al. 20-Year Trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry 2020; 177: 706-715
• 9 Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016; 18: 174-182
• 10 Mandal S, Mamidipalli SS, Mukherjee B. et al. Perspectives, attitude, and practice of lithium prescription among psychiatrists in India. Indian J Psychiatry 2019; 61: 451-456
• 11 Parabiaghi A, Barbato A, Risso P. et al. Lithium use from 2000 to 2010 in Italy: A population-based study. Pharmacopsychiatry 2015; 48: 89-94
• 12 Poranen J, Koistinaho A, Tanskanen A. et al. Twenty-year medication use trends in first-episode bipolar disorder. Acta Psychiatr Scand 2022; 146: 583-593
• 13 Shafiq S, Ronksley PE, Scory TD. et al. Ten-year trends in lithium prescribing in Alberta, Canada. Can J Psychiatry 2023; 69: 13–20
• 14 Bridler R, Haberle A, Muller ST. et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol 2015; 25: 763-772
• 15 Glocker C, Grohmann R, Burkhardt G. et al. Antipsychotic drug-induced neutropenia: Results from the AMSP drug surveillance program between 1993 and 2016. J Neural Transm (Vienna) 2023; 130: 153-163
• 16 Seifert J, Maier HB, Fuhrmann F. et al. Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: Results from the AMSP pharmacovigilance program from 2001-2017. J Neural Transm (Vienna) 2022; 129: 925-944
• 17 Lyall LM, Penades N, Smith DJ. Changes in prescribing for bipolar disorder between 2009 and 2016: National-level data linkage study in Scotland. Br J Psychiatry 2019; 215: 415-421
• 18 Lin CH, Chan HY, Chen CC. et al. Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006-2019. J Affect Disord 2022; 318: 386-392
• 19 Greil W, de Bardeci M, Muller-Oerlinghausen B. et al. Controversies regarding lithium-associated weight gain: Case-control study of real-world drug safety data. Int J Bipolar Disord 2023; 11: 34
• 20 Malhi GS, Bell E, Jadidi M. et al. Countering the declining use of lithium therapy: A call to arms. Int J Bipolar Disord 2023; 11: 30
• 21 Puranen A, Koponen M, Lahteenvuo M. et al. Real-world effectiveness of mood stabilizer use in schizophrenia. Acta Psychiatr Scand 2023; 147: 257-266
• 22 Baethge C, Gruschka P, Berghofer A. et al. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: Outcome after long-term follow-up. J Affect Disord 2004; 79: 43-50
• 23 Martin-Blanco A, Ancochea A, Soler J. et al. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand 2017; 136: 323-331
• 24 Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: A randomised study. J Affect Disord 1996; 40: 179-190
• 25 Coppen A, Abou-Saleh MT. Lithium in the prophylaxis of unipolar depression: A review. J R Soc Med 1983; 76: 297-301
• 26 Barnes TR, Drake R, Paton C. et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2020; 34: 3-78
• 27 Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 42-50
• 28 Kriner P, Severus E, Korbmacher J. et al. Lithium prescription trends in psychiatric inpatient care 2014 to 2021: Data from a Bavarian drug surveillance project. Int J Bipolar Disord 2023; 11: 40
• 29 Lohse MJ, Müller-Oerlinhausen B. Psychopharmaka. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J eds, Arzneiverordnungs-Report 2018. Berlin: Springer; 2018: 733-762
• 30 Tokumitsu K, Yasui-Furukori N, Adachi N. et al. Predictors of psychiatric hospitalization among outpatients with bipolar disorder in the real-world clinical setting. Front Psychiatry 2023; 14: 1078045